memantine clinical trials
Jump to navigation
Jump to search
Introduction
3 studies: 24 & 28 weeks,
- 2 studies used memantine 20 mg/day, one in combination with donepezil[1][2]
- 1 study used 5-20 mg of memantine in combination with donepezil[3]
- all 3 studies showed improvement in cognitive function & activities of daily living relative to placebo or donepezil alone
- improvement modest
- 3.4 points on a 100 point scale of cognitive function
- 1.5 points on a 54 point activities of daily living scale
Summary & Clinical practice guideline[4][5]
- statistically significant but clinically marginal improvement in measures of cognition & global assessment of dementia
- most studies were of short duration (6 months); this limits their ability to detect delay in onset or progression of dementia
More general terms
References
- ↑ 1.0 1.1 Journal Watch 23(10):80, 2003 Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12672860
- ↑ 2.0 2.1 Prescriber's Letter 10(11) 2003; detail document 191102 http://www.namenda.com
- ↑ 3.0 3.1 Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14734594
- ↑ 4.0 4.1 Raina P et al Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008 Mar 4;148(5):379-97 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18316756
- ↑ 5.0 5.1 Kavirajan H, Schneider LS Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 Sep;6(9):782-92 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17689146